The Motley Fool
07 Jun 2026, 12:28 UTC · 15w ago
Verdict
Headline takes no side. We score LGND +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Filspari received FDA approval as the first treatment for focal segmental glomerulosclerosis (FSGS) on April 16, 2026.
So whatFirst-to-market FDA approval for a specific indication typically drives significant revenue growth and increases company valuation.
More positive than 99% of claims this week
Ligand's first-quarter royalty revenue grew 56% year-over-year to $43 million.
So whatStrong growth in high-margin royalty streams demonstrates the scalability of the company's business model.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 86% of claims this week
First-quarter sales of Captisol fell to $8.7 million from $13.5 million in the previous year.
More negative than 79% of claims this week
CLO and Secretary Andrew Reardon sold 5,000 shares of common stock for approximately $1.14 million via an option exercise.
More negative than 66% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
Strong growth in royalty revenue and a new FDA approval for Filspari outweigh a temporary dip in Captisol sales and executive stock selling.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
10h ago
+25.9%
Price agrees with the score
$298.41 vs $237.00 close before publication (Jun 5) · not market-adjusted
LGND chart →
